Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy

M Aubier, R Buhl, T Ekström, J Ostinelli, C P van Schayck, O Selroos, J Haughney

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The aim of this study was to compare two budesonide/formoterol maintenance doses within the budesonide/formoterol maintenance and reliever therapy concept and to identify possible patient characteristics at baseline which would predict a better response to a higher than standard maintenance dose. A total of 8,424 patients with symptomatic asthma when using an inhaled corticosteroid (ICS) with or without a long-acting β(2)-agonist were randomised to budesonide/formoterol 160/4.5 μg, one (1 × 2) or two (2 × 2) inhalations b.i.d. Patients used the same inhaler as needed for symptom relief. The primary outcome variable was time to first severe asthma exacerbation. In the total study population, the time to first severe asthma exacerbation was prolonged by 18% with 2 × 2 versus 1 × 2 (hazard ratio 0.82; p = 0.03). Lung function (peak expiratory flow) was the only statistically significant predictor of a better response to 2 × 2. The mean daily ICS doses were 737 and 463 μg in the 2 × 2 and 1 × 2 groups, respectively. In a real-life setting, budesonide/formoterol maintenance and reliever therapy at the 2 × 2 maintenance dose did prolong time to first severe exacerbation but at a higher medication load. Patients with low lung function benefited most from the higher maintenance dose.

Original languageEnglish
Pages (from-to)524-530
Number of pages7
JournalEuropean Respiratory Journal
Volume36
Issue number3
DOIs
Publication statusPublished - 1 Sep 2010

Fingerprint

Budesonide
Maintenance
Asthma
Adrenal Cortex Hormones
Lung
Nebulizers and Vaporizers
Therapeutics
Inhalation
Formoterol Fumarate
Population

Keywords

  • administration, inhalation
  • adolescent
  • adrenal cortex hormones
  • adult
  • aged
  • aged, 80 and over
  • asthma
  • budesonide
  • drug administration schedule
  • ethanolamines
  • female
  • formoterol fumarate
  • humans
  • male
  • middle aged
  • nebulizers and vaporizers
  • research design
  • time factors

Cite this

Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. / Aubier, M; Buhl, R; Ekström, T; Ostinelli, J; van Schayck, C P; Selroos, O; Haughney, J.

In: European Respiratory Journal, Vol. 36, No. 3, 01.09.2010, p. 524-530.

Research output: Contribution to journalArticle

Aubier, M ; Buhl, R ; Ekström, T ; Ostinelli, J ; van Schayck, C P ; Selroos, O ; Haughney, J. / Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy. In: European Respiratory Journal. 2010 ; Vol. 36, No. 3. pp. 524-530.
@article{693c861c5cec4327af9e25af99019860,
title = "Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy",
abstract = "The aim of this study was to compare two budesonide/formoterol maintenance doses within the budesonide/formoterol maintenance and reliever therapy concept and to identify possible patient characteristics at baseline which would predict a better response to a higher than standard maintenance dose. A total of 8,424 patients with symptomatic asthma when using an inhaled corticosteroid (ICS) with or without a long-acting β(2)-agonist were randomised to budesonide/formoterol 160/4.5 μg, one (1 × 2) or two (2 × 2) inhalations b.i.d. Patients used the same inhaler as needed for symptom relief. The primary outcome variable was time to first severe asthma exacerbation. In the total study population, the time to first severe asthma exacerbation was prolonged by 18{\%} with 2 × 2 versus 1 × 2 (hazard ratio 0.82; p = 0.03). Lung function (peak expiratory flow) was the only statistically significant predictor of a better response to 2 × 2. The mean daily ICS doses were 737 and 463 μg in the 2 × 2 and 1 × 2 groups, respectively. In a real-life setting, budesonide/formoterol maintenance and reliever therapy at the 2 × 2 maintenance dose did prolong time to first severe exacerbation but at a higher medication load. Patients with low lung function benefited most from the higher maintenance dose.",
keywords = "administration, inhalation, adolescent, adrenal cortex hormones, adult, aged, aged, 80 and over, asthma, budesonide, drug administration schedule, ethanolamines, female, formoterol fumarate, humans, male, middle aged, nebulizers and vaporizers, research design, time factors",
author = "M Aubier and R Buhl and T Ekstr{\"o}m and J Ostinelli and {van Schayck}, {C P} and O Selroos and J Haughney",
year = "2010",
month = "9",
day = "1",
doi = "10.1183/09031936.00022010",
language = "English",
volume = "36",
pages = "524--530",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Comparison of two twice-daily doses of budesonide/formoterol maintenance and reliever therapy

AU - Aubier, M

AU - Buhl, R

AU - Ekström, T

AU - Ostinelli, J

AU - van Schayck, C P

AU - Selroos, O

AU - Haughney, J

PY - 2010/9/1

Y1 - 2010/9/1

N2 - The aim of this study was to compare two budesonide/formoterol maintenance doses within the budesonide/formoterol maintenance and reliever therapy concept and to identify possible patient characteristics at baseline which would predict a better response to a higher than standard maintenance dose. A total of 8,424 patients with symptomatic asthma when using an inhaled corticosteroid (ICS) with or without a long-acting β(2)-agonist were randomised to budesonide/formoterol 160/4.5 μg, one (1 × 2) or two (2 × 2) inhalations b.i.d. Patients used the same inhaler as needed for symptom relief. The primary outcome variable was time to first severe asthma exacerbation. In the total study population, the time to first severe asthma exacerbation was prolonged by 18% with 2 × 2 versus 1 × 2 (hazard ratio 0.82; p = 0.03). Lung function (peak expiratory flow) was the only statistically significant predictor of a better response to 2 × 2. The mean daily ICS doses were 737 and 463 μg in the 2 × 2 and 1 × 2 groups, respectively. In a real-life setting, budesonide/formoterol maintenance and reliever therapy at the 2 × 2 maintenance dose did prolong time to first severe exacerbation but at a higher medication load. Patients with low lung function benefited most from the higher maintenance dose.

AB - The aim of this study was to compare two budesonide/formoterol maintenance doses within the budesonide/formoterol maintenance and reliever therapy concept and to identify possible patient characteristics at baseline which would predict a better response to a higher than standard maintenance dose. A total of 8,424 patients with symptomatic asthma when using an inhaled corticosteroid (ICS) with or without a long-acting β(2)-agonist were randomised to budesonide/formoterol 160/4.5 μg, one (1 × 2) or two (2 × 2) inhalations b.i.d. Patients used the same inhaler as needed for symptom relief. The primary outcome variable was time to first severe asthma exacerbation. In the total study population, the time to first severe asthma exacerbation was prolonged by 18% with 2 × 2 versus 1 × 2 (hazard ratio 0.82; p = 0.03). Lung function (peak expiratory flow) was the only statistically significant predictor of a better response to 2 × 2. The mean daily ICS doses were 737 and 463 μg in the 2 × 2 and 1 × 2 groups, respectively. In a real-life setting, budesonide/formoterol maintenance and reliever therapy at the 2 × 2 maintenance dose did prolong time to first severe exacerbation but at a higher medication load. Patients with low lung function benefited most from the higher maintenance dose.

KW - administration, inhalation

KW - adolescent

KW - adrenal cortex hormones

KW - adult

KW - aged

KW - aged, 80 and over

KW - asthma

KW - budesonide

KW - drug administration schedule

KW - ethanolamines

KW - female

KW - formoterol fumarate

KW - humans

KW - male

KW - middle aged

KW - nebulizers and vaporizers

KW - research design

KW - time factors

U2 - 10.1183/09031936.00022010

DO - 10.1183/09031936.00022010

M3 - Article

VL - 36

SP - 524

EP - 530

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

ER -